Functional connectivity to the premotor cortex maps onto longitudinal brain neurodegeneration in progressive apraxia of speech.
Aphasia
Apraxia of speech
Functional connectivity
Longitudinal neurodegeneration
Multimodal imaging
Journal
Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
25
03
2022
revised:
27
08
2022
accepted:
30
08
2022
pubmed:
28
9
2022
medline:
26
10
2022
entrez:
27
9
2022
Statut:
ppublish
Résumé
Primary progressive apraxia of speech (PPAOS) is a neurodegenerative motor speech disorder affecting the ability to produce speech. If agrammatic aphasia is present, it can be referred to as the non-fluent/agrammatic variant of primary progressive aphasia (nfvPPA). We investigated whether resting-state functional MRI (rs-fMRI) connectivity from disease "epicenters" correlated with longitudinal gray matter atrophy and hypometabolism in nfvPPA and PPAOS. Eighteen nfvPPA and 23 PPAOS patients underwent clinical assessment, structural MRI, rs-fMRI, and [
Identifiants
pubmed: 36166918
pii: S0197-4580(22)00188-9
doi: 10.1016/j.neurobiolaging.2022.08.013
pmc: PMC9613616
mid: NIHMS1834903
pii:
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-116Subventions
Organisme : NIDCD NIH HHS
ID : R01 DC010367
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC012519
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC014942
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest M.L.S. has owned stocks, within the past 12 months, in Align Technology, Inc., Inovio Pharmaceuticals Inc., LHC Group, Inc., Mesa Laboratories, Inc., and Natus Medical Inc., unrelated to the current study. V.J.L. consults for Bayer Schering Pharma, Piramal Life Sciences, Life Molecular Imaging, Eisai Inc., AVID Radiopharmaceuticals, and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals. C.R.J. serves on a scientific advisory board for Eli Lilly & Company, as a speaker for Eisai and on an independent data safety monitoring board for Roche but he receives no personal compensation from any commercial entity. All other authors report no competing interests for this study.
Références
Brain. 1962 Dec;85:665-78
pubmed: 14026018
Brain. 2008 Mar;131(Pt 3):665-80
pubmed: 18263627
Brain Lang. 2013 Nov;127(2):106-20
pubmed: 23218686
Neuroimage. 2020 Oct 15;220:117038
pubmed: 32585343
Stroke. 2016 Jan;47(1):31-6
pubmed: 26645260
Brain. 2006 Jun;129(Pt 6):1385-98
pubmed: 16613895
Neurology. 2013 Feb 12;80(7):634-41
pubmed: 23345641
Brain. 2014 Oct;137(Pt 10):2783-95
pubmed: 25113789
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2871-5
pubmed: 25730850
Neuroimage Clin. 2019;21:101594
pubmed: 30514656
Cereb Cortex. 2016 Aug;26(8):3508-26
pubmed: 27230218
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neuron. 2012 Mar 22;73(6):1216-27
pubmed: 22445348
Brain. 2020 May 1;143(5):1555-1571
pubmed: 32438414
Nat Commun. 2022 Mar 15;13(1):1362
pubmed: 35292638
Brain. 2016 Feb;139(Pt 2):547-62
pubmed: 26586695
Cortex. 2017 Dec;97:143-159
pubmed: 29102243
Neuroimage Clin. 2018 Mar 03;18:617-629
pubmed: 29845010
Brain. 2019 Aug 1;142(8):2466-2482
pubmed: 31199471
Neurology. 2013 Jul 23;81(4):337-45
pubmed: 23803320
Arch Clin Neuropsychol. 1999 Aug;14(6):481-7
pubmed: 14590575
Nat Commun. 2020 Jan 17;11(1):347
pubmed: 31953405
Neurology. 2013 Jan 29;80(5):496-503
pubmed: 23359374
Neuroimage. 2015 Jun;113:61-9
pubmed: 25797830
JAMA Netw Open. 2022 Apr 1;5(4):e229588
pubmed: 35486397
Cereb Cortex. 2021 Feb 5;31(3):1693-1706
pubmed: 33152765
Neuroimage Clin. 2021;32:102850
pubmed: 34655905
Curr Neurol Neurosci Rep. 2015 Jul;15(7):44
pubmed: 26008810
Cortex. 2017 May;90:138-148
pubmed: 27771043
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Neurology. 2011 Jul 12;77(2):101-9
pubmed: 21613601
Neurology. 2016 Apr 12;86(15):1393-1399
pubmed: 26992858
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Cortex. 2015 Aug;69:220-36
pubmed: 26103600
Curr Opin Neurobiol. 2013 Apr;23(2):250-4
pubmed: 23146876
J Commun Disord. 2014 Sep-Oct;51:43-50
pubmed: 25092638
Curr Opin Neurobiol. 2017 Jun;44:127-131
pubmed: 28486176
Front Neurol. 2018 Sep 18;9:766
pubmed: 30279675
Nat Commun. 2021 Jun 8;12(1):3452
pubmed: 34103532
Neuroimage Clin. 2020;28:102408
pubmed: 33353609
Brain. 2016 Oct;139(Pt 10):2778-2791
pubmed: 27497488
Brain Lang. 2013 Jun;125(3):245-52
pubmed: 23542727
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
Am J Alzheimers Dis Other Demen. 2009 Oct-Nov;24(5):408-16
pubmed: 19700669
Brain. 2018 Jan 1;141(1):302-317
pubmed: 29228180
Brain. 2012 May;135(Pt 5):1522-36
pubmed: 22382356
Neurology. 2017 Nov 28;89(22):2271-2279
pubmed: 29093069
Prog Neurobiol. 2021 Apr;199:101951
pubmed: 33189781
Neurocase. 2018 Apr;24(2):111-120
pubmed: 29799310
Brain Lang. 2018 Sep;184:54-65
pubmed: 29980072
Neuroimage Clin. 2015 Jan 22;8:345-55
pubmed: 26106560
Nat Commun. 2020 May 26;11(1):2612
pubmed: 32457389
JAMA Netw Open. 2021 Mar 1;4(3):e211290
pubmed: 33704477
JAMA Netw Open. 2020 Oct 1;3(10):e2022847
pubmed: 33112398
Ann Neurol. 2006 Apr;59(4):673-81
pubmed: 16470518
Lancet Neurol. 2018 Mar;17(3):241-250
pubmed: 29397305
Neurol Clin Pract. 2021 Jun;11(3):249-255
pubmed: 34484892
Neurology. 2014 Jan 21;82(3):239-47
pubmed: 24353332
Brain. 2008 Nov;131(Pt 11):2957-68
pubmed: 18829698